Motor subtype in Parkinson's disease: Different disorders or different stages of disease?

Movement Disorders

Volumn 31, Issue 7, 2016, Pages 957-961

  Nutt, John G ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; SELEGILINE; TOCOPHEROL;

ARTICLE; CLINICAL ASSESSMENT; CLUSTER ANALYSIS; DISEASE COURSE; HUMAN; LABORATORY TEST; MOTOR DYSFUNCTION; NEUROIMAGING; NEUROPATHOLOGY; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SYSTEMATIC REVIEW (TOPIC); TREMOR;

EID: 84977590156     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26657     Document Type: Article

References (37)

1. Sieber BA, Landis S, Koroshetz W, et al. Prioritized research recommendations from the National Institute of Neurological Disorders and Stroke Parkinson's Disease 2014 conference. Ann Neurol 2014;76:469-472.
2. Jamieson NB, Chang DK, Biankin AV. Cancer genetics and implications for clinical management. Surg Clin North Am 2015;95:919-934.
3. Jankovic J, McDermott M, Carter J, et al. Variable expression of parkinson's disease: a base-line analysis of the DATATOP cohort. Neurology 1990; 40:1529-1534.
4. Stebbins GT, Goetz CG, Burn DJ, et al. How to identify tremor dominant and postural instability/gait difficulty groups with the movement Disorder Society Unified Parkinson's Disease Rating Scale: comparison with the Unified Parkinson's Disease Rating Scale. Mov Disord 2013;28:668-670.
5. Rajput AH, Voll A, Rajput ML, et al. Course in Parkinson disease subtypes: a 39-year clinicopathologic study. Neurology 2009;73:206-212.
6. Marras C, Lang, A. Parkinson's disease subtypes: lost in translation? J Neurol Neurosurg Psychiatry 2013;84:409-415.
7. Thenganatt MA, Jankovic J. Parkinson disease subtypes. JAMA Neurol 2014;71:499-504.
8. Vu TC, Nutt JG, Holford NH. Disease progress and response to treatment as predictors of survival, disability, cognitive impairment and depression in Parkinson's disease. Br J Clin Pharmacol 2012;74:284-295.
9. Alves G, Larsen JP, Emre M, et al. Changes in motor subtype and risk for incident dementia in Parkinson's disease. Mov Disord 2006;21:1123-1130.
10. Josephs KA, Matsumoto JY, Ahlskog JE. Benign tremulous parkinsonism. Arch Neurol 2006;63:354-357.
11. Selikhova M, Williams DR, Kempster PA, et al. A clinico-pathological study of subtypes in Parkinson's disease. Brain 2009;132:2947-2957.
12. Selikhova M, Kempster PA, Revesz T, et al. Neuropathological findings in benign tremulous parkinsonism. Mov Disord 2013;28:145-152.
13. Deuschl G. Benign tremulous Parkinson's disease: a misnomer? Mov Disord 2013;28:117-119.
14. Lewis SJ, Foltynie T, Blackwell AD, et al. Heterogeneity of Parkinson's disease in the early clinical stages using a data driven approach. J Neurol Neurosurg Psychiatry 2005;76:343-348.
15. Fereshtehnejad SM, Romenets SR, Anang JB, et al. New clinical subtypes of Parkinson disease and their longitudinal progression: a prospective cohort comparison with other phenotypes. JAMA Neurol 2015;72:863-873.
16. Marras C. Subtypes of Parkinson's disease: state of the field and future directions. Curr Opin Neurol 2015;28:382-386.
17. Tanner CM, Ross GW, Jewell SA, et al. Occupation and risk of parkinsonism: a multicenter case-control study. Arch Neurol 2009;66:1106-1113.
18. Alcalay RN, Mejia-Santana H, Tang MX, et al. Motor phenotype of LRRK2 G2019S carriers in early-onset Parkinson disease. Arch Neurol 2009;66:1517-1522.
19. Healy DG, Falchi M, O'Sullivan SS, et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol 2008;7:583-590.
20. Sidransky E, Nalls MA, Aasly JO, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med 2009;361:1651-1661.
21. Brockmann K, Srulijes K, Pflederer S, et al. GBA-associated Parkinson's disease: reduced survival and more rapid progression in a prospective longitudinal study. Mov Disord 2015;30:407-411.
22. Di Battista ME, Pascale E, Purcaro C, et al. Clinical subtypes in Parkinson's disease: the impact of MAPT haplotypes. J Neural Transm (Vienna) 2014;121:353-356.
23. Paulus W, Jellinger K. The neuropathologic basis of different clinical subgroups of Parkinson's disease. J Neuropathol Exp Neurol 1991;50:743-755.
24. Greffard S, Verny M, Bonnet AM, et al. Motor score of the Unified Parkinson Disease Rating Scale as a good predictor of Lewy body-associated neuronal loss in the substantia nigra. Arch Neurol 2006;63:584-588.
25. Eggers C, Kahraman D, Fink GR, et al. Akinetic-rigid and tremor-dominant Parkinson's disease patients show different patterns of FP-CIT single photon emission computed tomography. Mov Disord 2011;26:416-423.
26. Kaasinen V, Kinos M, Joutsa J, et al. Differences in striatal dopamine transporter density between tremor dominant and non-tremor Parkinson's disease. Eur J Nucl Med Mol Imaging 2014;41:1931-1937.
27. Moccia M, Pappata S, Picillo M, et al. Dopamine transporter availability in motor subtypes of de novo drug-naive Parkinson's disease. J Neurol 2014;261:2112-2118.
28. Song IU, Chung YA, Oh JK, et al. An FP-CIT PET comparison of the difference in dopaminergic neuronal loss in subtypes of early Parkinson's disease. Acta Radiol 2014;55:366-371.
29. Rosenberg-Katz K, Herman T, Jacob Y, et al. Gray matter atrophy distinguishes between Parkinson disease motor subtypes. Neurology 2013;80:1476-1484.
30. Vervoort G, Bengevoord A, Nackaerts E, et al. Distal motor deficit contributions to postural instability and gait disorder in Parkinson's disease. Behav Brain Res 2015; 287:1-7.
31. Kang JH, Irwin DJ, Chen-Plotkin AS, et al. Association of cerebrospinal fluid beta-amyloid 1-42, T-tau, P-tau181, and alpha-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol 2013;70:1277-1287.
32. Antonini A, Vontobel P, Psylla M, et al. Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease. Arch Neurol 1995;52:1183-1190.
33. Pavese N, Evans AH, Tai YF, et al. Clinical correlates of levodopa-induced dopamine release in Parkinson disease: a PET study. Neurology 2006;67:1612-1617.
34. Ma Y, Tang C, Spetsieris PG, et al. Abnormal metabolic network activity in Parkinson's disease: test-retest reproducibility. J Cereb Blood Flow Metab 2007;27:597-605.
35. Mure H, Hirano S, Tang CC, et al. Parkinson's disease tremor-related metabolic network: characterization, progression, and treatment effects. Neuroimage 2011;54:1244-1253.
36. Louis ED, Tang MX, Cote L, et al. Progression of parkinsonian signs in Parkinson disease. Arch Neurol 1999;56:334-337.
37. Neumann J, Bras J, Deas E, et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain 2009;132:1783-1794.